The past year was another noteworthy one with respect to securities fraud class action lawsuits against life sciences companies. There was a meaningful increase in the number of securities fraud lawsuits and a continued emphasis on industry-specific allegations of material misstatements and omissions. Although life sciences companies continue to enjoy relative success in obtaining early dismissals of these cases, the large-scale risks that follow from a securities fraud class action will only be magnified by a recent U.S. Supreme Court decision regarding class certification.
